Amgen Reports Landmark Survival Data; Brazil Court Orders Meta to Halt Election Interference

By / / Breaking News

This update was written automatically with AI from market data and news wire reports, and published without review by a person.

Key Takeaways

  • Amgen (AMGN) announced that its drug Imdelltra, in combination with AstraZeneca’s (AZN) Imfinzi, reduced the risk of death by 58% in first-line extensive-stage small cell lung cancer (ES-SCLC).
  • The combination therapy extended median overall survival to 21.1 months, compared to 12.7 months for patients receiving Imfinzi alone.
  • Brazil’s Superior Electoral Court (TSE) ordered Meta (META) to stop interfering with political content distribution following allegations of bias from President Lula’s campaign.
  • The court has threatened Meta with daily fines of up to 1 million reais ($200,000) if it fails to ensure equal treatment between candidates ahead of Sunday's presidential runoff.

Amgen’s "Watershed" Breakthrough in Lung Cancer Treatment

Amgen (AMGN) released landmark results from its Phase 3 DeLLphi-305 trial today, showing that Imdelltra (tarlatamab-dlle) significantly improves survival rates for patients with aggressive lung cancer. When used as a first-line maintenance treatment alongside AstraZeneca’s (AZN) Imfinzi (durvalumab), the regimen more than tripled progression-free survival.

The data, presented at the ESMO Congress 2026, revealed that nearly 80% of patients on the combination therapy were alive at one year, compared to 53% in the control group. While the safety profile remained consistent with individual medicines, Grade 3 or higher adverse events occurred in 20.9% of combination patients versus 10.8% for those on Imfinzi alone. Analysts suggest these results could establish a new standard of care for ES-SCLC, a disease historically known for poor prognosis.

Brazil’s Electoral Court Cracks Down on Meta and X

In a major escalation of election oversight, Brazil’s Superior Electoral Court has ordered Meta (META) to cease any actions that restrict the reach of political content. The ruling follows a formal complaint from President Luiz Inácio Lula da Silva’s campaign, which alleged that the company’s algorithms and Meta AI were suppressing his posts while favoring his opponent, Flávio Bolsonaro.

The dispute has intensified just days before the high-stakes presidential runoff scheduled for Sunday. Judges have demanded technical explanations from both Meta (META) and X (formerly Twitter) regarding their content distribution practices. While Meta has denied any political bias, attributing the issues to "technical problems" and global glitches, the court has doubled non-compliance fines to 1 million reais ($200,000) per day to ensure a level playing field.

Market Implications and Regulatory Pressure

The legal pressure in Brazil reflects a growing global trend of judicial intervention in social media's role during democratic processes. Similar to recent cases in Germany and Romania, Brazilian authorities are focusing on algorithmic transparency and the potential for AI-generated content to sway voter sentiment.

For Amgen (AMGN), the clinical success of Imdelltra is expected to bolster its oncology portfolio significantly. With a reported 58% reduction in the risk of death, the drug is positioned to capture a substantial share of the maintenance therapy market for small cell lung cancer. Investors are closely watching for further regulatory filings as the company seeks to expand the drug's label for earlier-line treatment.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top